Radioimmunoconjugates targeting grp78 for use in the treatment of cancer
AssigneeActinium Pharmaceuticals, Inc.
InventorsDale L. LUDWIG, Eileen GEOGHEGAN, Helen KOTANIDES, Sandesh SETH
Life of this patent
Estimating the term…
Loading patent…
AssigneeActinium Pharmaceuticals, Inc.
InventorsDale L. LUDWIG, Eileen GEOGHEGAN, Helen KOTANIDES, Sandesh SETH
Estimating the term…
Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface GRP78, alone or in combination with other therapies, are provided. The radiolabeled GRP78 targeting agent delivers radiation to cells that externally present GRP78, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled GRP78 targeting agent itself increases the cell surface expression of GRP78, leading to a feed-forward mechanism that drives further accumulation of the GRP78 targeting agent at target lesions to enhance its therapeutic effect.
1-12. (canceled)
A method for treating a cancer or precancerous disorder in a mammalian subject, comprising:
23-40. (canceled)
Dependencies are inferred from the claim text.